Subject: FW: DiFusion Follow-Up
From: "Derrick Johns" <[email-masked]>
To: <[email-masked]>
Cc: <[email-masked]>
Date: Wed, 19 Nov 2014 08:58:33 -0700

CONFIDENTIAL 

Just so you guys know you¹re not spinning wheels.   Zimmer just bought
Biomet for $13.5 billionŠthey know we are a threatŠlittle old usŠand looking
to do a ³pre emptive deal² see below - So is NuVasive whose emails I will
send out behind this.   Our science is great, my connections are notŠ

The warrants will bring great value and Evan is working on a draft.

Derrick W. Johns
CEO and Founder
www.difusiontech.com

"All Truths are easy to understand once discovered,
             the point is to discover them²  - Galileo

(512) 863-7777 o
(512) 284-3338 c

From:  "Smyth, Linda" <[email-masked]>
Date:  Tuesday, November 18, 2014 at 10:29 AM
To:  Derrick Johns <[email-masked]>
Cc:  "Cloar, Jim" <[email-masked]>
Subject:  RE: DiFusion Follow-Up

Hi Derrick,
 
We appreciate your taking the time to meet with us during NASS.  We are
looking forward to receiving the instructions for the clinical data room.  I
will send you a confirmation email as soon as we receive it.
 
Best,
 
Linda

From: Derrick Johns [mailto:[email-masked]]
Sent: Monday, November 17, 2014 10:07 PM
To: Cloar, Jim; Smyth, Linda
Subject: DiFusion Follow-Up
Importance: High

Jim and Linda,

Thank for taking to the time to learn more about our science and corporate
direction at NASS.   To make further evaluation easier for you, I have asked
our counsel to add you to our clinical data room with others instead of
doing an email dump.   We have not asked any strategics for NDA¹s given our
IP and will not require one for Biomet.

As we discussed I think Zimmer Biomet could especially benefit from
CleanFuze and the contracting leverage an antimicrobial / osteoconductive
material would provide against bigger players like Depuy across spine and
total joint.   We will begin our PMS for ³fusion equivalency² with Professor
Meisel, MD, Ph.D. in Q1 upon receipt of our SBIR Phase II Grant.  That would
be the window in which our Board would want to be closing any milestone or
First Right deals to avoid engaging VC¹s in front of FDA clearance.(Q3 2015
FDA Clearance, Master File Submitted 11/09/14  Pre Sub Meeting complete).
That would only require a small capital infusion in January and not detract
resources from your current closing.

You will both receive invites to our scientific data room shortly.   Again,
it was a pleasure meeting you both.

Derrick W. Johns

CEO and Founder

www.difusiontech.com <http://www.difusiontech.com>

"All Truths are easy to understand once discovered,

             the point is to discover them²  - Galileo

(512) 863-7777 o

(512) 284-3338 c